PARP Inhibitors in BRCA Gene-Mutated Ovarian Cancer and Beyond

被引：0
作者：
Susana Banerjee
Stan Kaye
机构：
[1] Gynaecology Unit,Division of Clinical Studies, Institute of Cancer Research, Drug Development Unit
[2] The Royal Marsden NHS Foundation Trust,undefined
[3] The Royal Marsden NHS Foundation Trust,undefined
来源：
Current Oncology Reports | 2011年 / 13卷
关键词：
PARP inhibitors; Ovarian cancer; BRCA; Olaparib; Endometrial;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Poly(ADP-ribose)polymerase (PARP) inhibitors are showing considerable promise for the treatment of BRCA mutation–associated ovarian and breast cancer. This approach exploits a synthetic lethal strategy to target the specific DNA repair pathway in cancers that harbor mutations in the BRCA1 or BRCA2 genes. Accumulating evidence suggests that PARP inhibitors may have a wider application in the treatment of sporadic, high-grade serous ovarian cancers and other cancers including endometrial cancer. In this review, we discuss the clinical development of PARP inhibitors in ovarian cancer and explore challenges that need to be addressed if the full potential of these agents is to be realized.
引用
收藏
页码：442 / 449
页数：7
相关论文
共 200 条
[1]  
Ashworth A(2008)A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair J Clin Oncol 26 3785-3790
[2]  
Patel KJ(1998)Involvement of Brca2 in DNA repair Mol Cell 1 347-357
[3]  
Yu VP(2001)Mutation in Brca2 stimulates error-prone homology-directed repair of DNA double-strand breaks occurring between repeated sequences EMBO J 20 4704-4716
[4]  
Lee H(2002)Brca2 (XRCC11) deficiency results in radioresistant DNA synthesis and a higher frequency of spontaneous deletions Mol Cell Biol 22 669-679
[5]  
Corcoran A(2000)Clinicopathologic features of BRCA-linked and sporadic ovarian cancer JAMA 283 2260-2265
[6]  
Thistlethwaite FC(2002)Effect of BRCA mutations on the length of survival in epithelial ovarian tumors J Clin Oncol 20 463-466
[7]  
Evans MJ(2008)“BRCAness” syndrome in ovarian cancer: a case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA1 and BRCA2 mutations J Clin Oncol 26 5530-5536
[8]  
Tutt A(2001)Genome maintenance mechanisms for preventing cancer Nature 411 366-374
[9]  
Bertwistle D(2010)Making the best of PARP inhibitors in ovarian cancer Nat Rev Clin Oncol 7 508-19
[10]  
Valentine J(2005)The concept of synthetic lethality in the context of anticancer therapy Nat Rev Canc 5 689-698
12345678910